Literature DB >> 7337430

Functional analysis of influenza RNA polymerase activity by the use of caps, oligonucleotides and polynucleotides.

S Stridh, B Oberg, J Chattopadhyaya, S Josephson.   

Abstract

The effects of caps, dinucleotides, oligonucleotides and polynucleotides on influenza virus RNA polymerase activity have been investigated. The results show that both methyl groups in a cap are necessary for optimal stimulation of polymerase activity. Both m7G(5')ppp(5')Am and ApG stimulated the influenza RNA polymerase activity and seemed to interact at different sites. Out of the 16 homopolynucleotides tested, seven inhibited influenza RNA polymerase by 50% at 2-10 micrograms/ml. Poly(G) gave a 90% reduction of influenza virus plaque formation at 10 micrograms/ml. An oligodeoxyribonucleotide complementary to the 12 terminal nucleotides of the 3' end of influenza virus RNA was synthesized. This oligonucleotide did not selectively inhibit influenza RNA polymerase.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7337430     DOI: 10.1016/0166-3542(81)90036-x

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  4 in total

1.  Determination of ribonucleoside triphosphate pools in influenza A virus-infected MDCK cells.

Authors:  S Stridh
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

2.  Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages.

Authors:  C J Marcus-Sekura; A M Woerner; K Shinozuka; G Zon; G V Quinnan
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

3.  Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent.

Authors:  A Zerial; N T Thuong; C Hélène
Journal:  Nucleic Acids Res       Date:  1987-12-10       Impact factor: 16.971

4.  Chapter 3 Antiviral drugs: general considerations.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.